In a 50-patient trial conducted by Hofman et al using LuPSMA alone against mCRPC, median OS was 13.3 months.
Median OS in the 56-patient LuPIN trial using LuPSMA + NOX66 was 19.7 months.
There was one significant difference: the LuPIN patients were MORE resistant to treatment, having had to have failed more prior therapies.
The LuPIN result was indeed remarkable.
Ann: LuPIN Survival Outcome Confirmed by Conference Presentation, page-10
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.5¢ | $1.863K | 16.19K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 103413 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 159073 | 5 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |